Emerging strategies in senotherapeutics: from broad-spectrum senolysis to precision reprogramming - PubMed
a day ago
- #aging
- #senotherapeutics
- #precision medicine
- Cellular senescence is a key mechanism in aging and age-related diseases.
- Early senolytics like navitoclax and D+Q showed promise but had drawbacks like thrombocytopenia and variable efficacy.
- Next-gen strategies include immune-based senolysis, tissue-precision PROTACs, and microbiome-epigenetic approaches.
- Immune-based senolysis targets immune evasion of senescent cells using methods like CAR T cells and metabolic vulnerabilities.
- Tissue-precision PROTACs degrade anti-apoptotic proteins locally to reduce systemic toxicity.
- Microbiome-epigenetic strategies use SCFAs and dietary interventions to enhance senolytic efficacy and modulate the SASP.
- Challenges remain, including immunopathology, manufacturing complexity, and long-term safety concerns.